Efficacy and adverse events (and consequent switch) was assumed. The cost-effectiveness acceptability curve derived from the probabilistic sensitivity analysis on the weekly mean percentage changes from baseline in the HAM-A score is shown on Figure 2. It is possible to see that 90 of the cases are below an ICER of 28.2 thousand euros.pregabalin, in which the switch specified by the panel was to